Tests While Taking Amlodipine

Unlike blockers of the renin-angiotensin system or diuretics, amlodipine has almost no effect on electrolytes and kidney function. That is why the question 'what tests should I take on amlodipine?' often causes surprise. Yet monitoring is needed - its main tools are simply different. The editorial team explains what to monitor and why, and where additional tests depend on concomitant medications.

Why Monitoring on Amlodipine Is Different

Amlodipine is a metabolically neutral drug. According to the FDA label and clinical studies, it does not cause clinically significant changes in potassium, sodium, glucose, lipids, or uric acid. Kidney function does not affect its pharmacokinetics, and the drug itself has no specific nephrotoxicity.

This distinguishes amlodipine from losartan or other RAAS blockers, where regular monitoring of potassium and creatinine is mandatory, as well as from thiazide diuretics, which affect electrolytes, glucose, and uric acid. For amlodipine, the labels do not provide for a separate 'laboratory safety program.'

This does not mean, however, that no tests are needed. First, a person with hypertension needs examination regardless of the drug - to assess cardiovascular risk and target-organ damage. Second, amlodipine is often part of combination tablets or is combined with other medications that have their own monitoring requirements.

And, finally, the most important 'test' on amlodipine is systematic measurement of blood pressure, which shows whether the treatment goal has been reached.

Blood Pressure: The Main Indicator

The goal of treating hypertension is to reach the target blood pressure level and maintain it. The European ESC/ESH 2018 and ESH 2023 guidelines recommend lowering blood pressure below 140/90 mm Hg for most patients, and, if well tolerated, to lower values taking into account age and comorbidities. Specific targets are determined by the doctor.

Since amlodipine reaches steady-state concentration only after about a week, the effect after starting or changing the dose should be assessed no earlier than 1-2 weeks later, and the full effect may develop even longer. Hasty conclusions after two or three days of use are incorrect.

• Home measurement- a validated upper-arm monitor, two measurements in the morning and evening over several days before the visit to the doctor.
• 24-hour monitoring (ABPM)- shows blood pressure over the day and at night, detects 'white-coat hypertension' and masked hypertension.
• Orthostatic test- measurement lying down and standing in older people and with dizziness.
• Heart rate- especially when combined with beta-blockers.

For people who train, it is important to measure blood pressure at rest, not immediately after a load, when it can be temporarily lowered. Records with date and time help the doctor assess the real picture.

Basic Laboratory Tests

During the diagnosis of hypertension and before starting treatment, the guidelines recommend a standard set of examinations. It is needed to assess overall risk, detect secondary causes of elevated pressure, and identify target-organ damage - heart, kidneys, vessels.

It is usually recommended to repeat these tests periodically, most often once a year, or more frequently in the presence of diabetes, kidney disease, or other comorbidities. The frequency is determined by the doctor.

Liver tests deserve a separate mention. Amlodipine is intensively metabolized in the liver, and in hepatic insufficiency its clearance decreases. The label mentions rare cases of elevated liver enzymes and jaundice. Therefore, in liver disease or with symptoms - dark urine, yellowing of the sclera, pain in the right upper quadrant - a test is needed.

Tests With Combinations and Concomitant Medications

Amlodipine is very often part of fixed combinations. In that case the monitoring requirements are determined by the 'partner' in the tablet. This is exactly where mistakes most often occur: the patient believes they are taking 'only amlodipine,' although the tablet contains another active component.

If amlodipine is combined with an ACE inhibitor or ARB, monitoring of potassium and creatinine is needed after starting and changing the dose - as with monotherapy with a RAAS blocker. If with a thiazide or thiazide-like diuretic - sodium, potassium, uric acid, and glucose are monitored.

When combined with simvastatin, a limit on the statin dose applies because of the risk of myopathy. Muscle pain and weakness are a reason to take a creatine phosphokinase (CK) test. People who train intensively should remember that CK rises after a hard workout even without any medications, so the test is best taken after several days of rest.

For post-transplant patients taking cyclosporine or tacrolimus, the label recommends monitoring the blood concentration of these drugs, since amlodipine may increase it.

When to See a Doctor Outside of Schedule

In addition to scheduled examinations, there are situations when you should not wait for the next visit. Some of them are related to the side effects of amlodipine, others to possible complications of hypertension itself.

An unscheduled examination is needed with pronounced or worsening leg swelling, especially one-sided and painful; with dizziness, fainting, or pressure consistently below the usual; with worsening chest pain after starting or changing the dose; with signs of liver damage.

You should also see a doctor if you plan to take new medications that affect CYP3A4 - for example, clarithromycin or some antifungals. A population study by Gandhi and colleagues (2013) showed that combining clarithromycin with calcium channel blockers in older people was associated with a higher risk of hypotension and acute kidney injury. Here, monitoring of blood pressure and creatinine may be needed.

A separate recommendation is regular visits to the dentist. Gum hyperplasia, described for calcium channel blockers, develops gradually, and it is easier to prevent with hygiene than to treat.

We also recommend familiarizing yourself with our materials on tests while taking losartan, on amlodipine's interactions with other drugs, and on the mechanism of action of bisoprolol.

Editorial Conclusions

Amlodipine is metabolically neutral and does not require specific laboratory safety monitoring, unlike RAAS blockers or diuretics. The main monitoring tool is regular measurement of blood pressure at home and, if needed, 24-hour monitoring.

Basic tests in hypertension - creatinine, electrolytes, glucose, lipids, albuminuria, ECG - are needed to assess overall risk regardless of the drug.

Additional tests are determined by the composition of the combination tablet and concomitant medications: potassium and creatinine with RAAS blockers, electrolytes and uric acid with diuretics, CK with muscle symptoms on statins.

References

1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
2. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071.
3. Norvasc (amlodipine besylate) tablets. Prescribing information. U.S. Food and Drug Administration.
4. Gandhi S, Fleet JL, Bailey DG, et al. Calcium-channel blocker–clarithromycin drug interactions and acute kidney injury and hypotension in older adults. JAMA. 2013;310(23):2544–2553.
5. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13–e115.